The primary reason for the success of CD19-based CAR design in eradicating hematologic malignancies is that CD19 is highly expressed on virtually all acute lymphoblastic leukemia cells, while other cells that express CD19 (B cells) are relatively discardable with the support of intravenous immunoglobulin (70). The gene discussed is CD19; the disease is acute lymphoblastic leukemia.